Vascular Dementia Market

Market Overview:

The 7 major vascular dementia markets reached a value of US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.89% during 2024-2034.

The vascular dementia market has been comprehensively analyzed in IMARC's new report titled "Vascular Dementia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vascular dementia refers to a medical disorder that develops when there is damage to the blood vessels that supply the brain. As a result, the flow of oxygen and nutrients to the brain is blocked, leading to cell death and cognitive decline. The common symptoms of this ailment include issues with memory, thinking, and reasoning; difficulties with problem-solving and decision-making; confusion; disorientation; trouble speaking or understanding language; etc. Individuals suffering from the illness may also experience mood changes, depression, agitation, anxiety, alterations in personality or behavior, an inability to create new memories, etc. The diagnosis of vascular dementia involves a comprehensive analysis of the patient's medical history, clinical features, and physical examination. The healthcare provider may further perform a magnetic resonance imaging (MRI) or computed tomography (CT) scan to identify any signs of abnormalities or brain damage, like infarcts, areas of reduced blood flow, white matter changes, etc. Various diagnostic tests, such as the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), are recommended to evaluate thinking abilities and cognitive functions in patients.

The increasing cases of strokes and small vessel diseases, which can lead to reduced or blocked blood flow to the brain, are primarily driving the vascular dementia market. In addition to this, the rising prevalence of several associated risk factors, including older age, high blood pressure, diabetes, smoking, elevated cholesterol, a history of heart disorders, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of occupational and speech therapies to help in enhancing communication skills and maintaining independence in the daily activities of life is further bolstering the market growth. Apart from this, the escalating application of cholinesterase inhibitors, such as donepezil, rivastigmine, galantamine, etc., for treating the illness is acting as another significant growth-inducing factor. These therapeutic agents work by increasing the levels of acetylcholine in the brain to improve cognitive function and memory. Additionally, the emerging popularity of non-invasive transcranial direct current stimulation techniques, owing to their several associated benefits, including promoting the neuron's ability to reorganize and form new connections with long-lasting effects, is expected to drive the vascular dementia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the vascular dementia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for vascular dementia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vascular dementia market in any manner.

Key Highlights:

• Vascular dementia is the second leading cause of dementia in the United States and Europe, although it is the most common type in some Asian countries.
• Vascular dementia has a prevalence rate of 1.5% in Western countries and about 2.2% in Japan.
• In Japan, vascular dementia accounts for half of all dementias that develop in adults older than 65 years.
• In Latin America, vascular dementia accounts for 15% of all dementia cases.
• Vascular dementia is more prevalent in men than in women.

Drugs:

BAC is a drug developed by Charsire Biotechnology Corporation to treat vascular dementia. It is a vapor fraction derived from soybean seeds, also known as CSTC1 or CHARSIRE Trauma Complex 1. BAC may help to reduce inflammation in the brain by inhibiting the expression of inflammatory factors.

Apabetalone is a drug being developed by Resverlogix Corporation as a potential treatment for vascular disease. Apabetalone is a small molecule that modulates disease-causing proteins by suppressing the action of BET and bromodomain proteins.  It inhibits BET proteins from attaching to acetylated lysines in histones, preventing them from triggering gene transcription.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the vascular dementia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the vascular dementia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vascular dementia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the vascular dementia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the vascular dementia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the vascular dementia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of vascular dementia across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of vascular dementia by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of vascular dementia by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with vascular dementia across the seven major markets?
• What is the size of the vascular dementia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of vascular dementia?
• What will be the growth rate of patients across the seven major markets?
   

Vascular Dementia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for vascular dementia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vascular dementia market?
• What are the key regulatory events related to the vascular dementia market?
• What is the structure of clinical trial landscape by status related to the vascular dementia market?
• What is the structure of clinical trial landscape by phase related to the vascular dementia market?
• What is the structure of clinical trial landscape by route of administration related to the vascular dementia market?